This conserved rate of HER2 positivity among IBC patient cases occurs even in areas of the world with historically higher incidence of the disease, such as Tunisia – where IBC accounts for approximately 6% of all breast cancer (contrasted with 2.5% IBC in our study) [26,27]. This evidence concerns the gene ERBB2 and breast carcinoma.